Abstract: An ultrasensitive method for detecting non-aromatic non-planar nitroamine analytes in a sample is provided.

Abstract: It is a subject of the present invention to provide a novel polymer; a filler for measuring a perfluoro compound having an acidic group at terminal which comprises said polymer; a column filled with said filler; and a measuring method for a perfluoro compound having an acidic group at terminal by using said column; as well as a filler for measuring a drug comprising the above-described polymer; a column filled with said filler; and a measuring method for a drug by using said column.

Abstract: A method of detecting melamine which includes providing a quantity of SERS-active particles and mixing the SERS-active particles with a solution containing melamine. The method further includes detecting a surface enhanced Raman spectrum of the melamine. The foregoing method may optionally include aggregating the SERS-active particles. Aggregation may occur before or after the SERS-active particles are mixed with a solution containing melamine. The method of detecting melamine may optionally include concentration of the SERS-active particles. The method may further include mixing a chaotropic agent having a higher affinity for a selected binding site than melamine into the solution containing melamine. The method may further include mixing a quantity of a SERS-active standard having a known SERS spectrum with the solution containing melamine and SERS-active particles. Assay apparatus and systems are also disclosed.

Abstract: A FRET donor-acceptor pair for use as a biosensor, comprising at least two fluorescence proteins, wherein at least one fluorescence protein is stable with respect to a parameter to be detected by the biosensor and at least one fluorescence protein is unstable with respect to the parameter to be detected by the biosensor.

Abstract: The invention is directed to a method of identifying a patient undergoing periodic hemodialysis treatments at increased risk for death that includes determining at least one of the patient's clinical or biochemical parameters, consisting of serum bicarbonate concentration level, serum potassium concentration level, serum calcium concentration level, hemoglobin concentration level, serum phosphorus concentration level, neutrophil to lymphocyte ratio, equilibrated normalized protein catabolic rate (enPCR), equilibrated fractional clearance of total body water by dialysis and residual kidney function (eKdrt/V), EPO resistance index, transferrin saturation index, serum ferritin concentration level, serum creatinine concentration level, platelet count, Aspartat-Aminotransferase level, and Alanin-Aminotransferase level at periodic hemodialysis treatments, and identifying a patient as having an increased risk for death if the patient has a significant change in the rate of change of at least one of the patient's cli

Abstract: The response of a patient with an enteropathic disease to therapy, particularly a candidate therapy in a clinical trial setting, is assessed by detecting the ability of the patient to metabolize an orally administered CYP3A substrate. The CYP3A metabolism may be monitored in a variety of ways. Conveniently, the appearance of a metabolite of the CYP3A substrate is detected in a patient sample over a period of time following oral administration, e.g. in urine, plasma, breath, saliva, etc. The CYP3A substrate is optionally labeled, e.g. with an isotopic, fluorescent, etc. label.

Abstract: The present invention is directed to treatment methods of administering tetrahydrobiopterin, including in oral dosage forms, in intravenous formulations, and with food. Also disclosed herein are biopterin assays for measuring the amount of biopterin and metabolites of biopterin in a sample.

Abstract: A method for evaluating an odor generated when using a self-tanning agent, wherein at least one compound selected from pyrazine compounds represented by the following general formula (1) is used as an indicator substance: wherein R1 represents a methyl group, an ethyl group or an acetyl group, and R2, R3 and R4 independently represent a hydrogen atom or a methyl group.

Abstract: The present invention relates to imidazolium salts, particularly imidazolium salts of the general formula I as well as the respective carbene metal complexes and their utilisation as bioanalytical tags for biomolecules.

Abstract: A surface grafted conjugated polyelectrolyte (CPE) is formed by coupling a CPE by a coupling moiety to the surface of a substrate. The substrate can be of any shape and size, and for many uses of the surface grafted CPE, it is advantageous that the substrate is a nanoparticle or microparticle. Surface grafted CPEs are presented that use silica particles as the substrate, where a modified silane coupling agent connects the surface to the CPE by a series of covalent bonds. Two methods of preparing the surface grafted CPEs are presented. One method involves the inclusion of the surface being modified by the coupling agent and condensed with monomers that form the CPE in a grafted state to the substrate. A second method involves the formation of a CPE with terminal groups that are complimentary to functionality that has been placed on the surface of the substrate by reaction with a coupling agent. The surface grafted CPEs are also described for use as biosensors and biocides.

Abstract: The invention relates to methods for detecting the presence of a compound of formula I in a biological test sample: where R2, R3, and R4 are as defined in the specification; or a salt thereof.

Abstract: The present invention relates to providing improved hydrogen peroxide assays, as well as droplet actuators for conducting such assays. The droplet actuators of the invention may be used to conduct droplet-based hydrogen peroxide assays. They may also be associated with detectors for analyzing the results of the hydrogen peroxide assays of the invention. They may be provided as components of systems which control droplet operations and/or detection for conducting the hydrogen peroxide assays. Measurement by the detector may be used to quantify the presence of an analyte in a sample.

Abstract: Devices, methods and systems effective to evaluate a physical or chemical property of an ion exchange resin-treated biological fluid sample are provided.

Abstract: A chemical sensor is disclosed. The chemical sensor is an electronic device including in specific embodiments a first transistor and a second transistor. The first transistor includes a semiconducting layer made of a first semiconductor and carbon nanotubes. The second transistor includes a semiconducting layer made of a second semiconductor, and does not contain carbon nanotubes. The two transistors vary in their response to chemical compounds, and the differing response can be used to determine the identity of certain chemical compounds. The chemical sensor can be useful as a disposable sensor for explosive compounds such as trinitrotoluene (TNT). The electronic device is used in conjunction with an analyzer that processes information generated by the electronic device.

Abstract: Blood and tissue markers of the metabolic status, risk of health complications in Fabry disease patients and as a biomarker to follow the efficacy of treatment in animal models and patients with Fabry disease comprising tetrahydrobiopterin (BH4), precursors and metabolites of BH4, and other related co-factors is disclosed herein. The present invention further describes the use of BH4 therapy as a treatment option for Fabry disease to prevent, slow or reverses vascular cardiac and renal manifestations of Fabry disease.

Abstract: Chemoselective derivatization of biological amines, carboxylic acids, aldehydes or ketones are employed in methods to detect a plurality of components, or members of a component, such as metabolites, that vary in molecular structure. The methods of the invention can be employed in aqueous and nonaqueous conditions.

Abstract: Methods are described for measuring the amount of a vitamin B2 in a sample. More specifically, mass spectrometric methods are described for detecting and quantifying vitamin B2 in a sample utilizing on-line extraction methods coupled with tandem mass spectrometric techniques.

Abstract: Sensors and methods for determination of analytes are provided. Analytes including explosives (e.g., RDX or PETN) may be determined by monitoring, for example, a change in an optical signal of a material upon exposure to the analyte. In some embodiments, the analyte and the material may interact via a chemical reaction to form a new emissive species. Embodiments described herein may provide inexpensive sensors with high selectivity and sensitivity.

Abstract: The invention provides a method of detecting uracil. The method comprises reacting uracil with a compound represented by the formula (I) in the presence of an oxidant and a base to produce a fluorescent compound represented by the formula (II).

Abstract: A detection device for detecting analytes in liquid specimen is provided. The detection device comprises: a specimen chamber for collecting or storing a liquid specimen; a detecting chamber for containing a detecting element; and a through hole for transferring the liquid specimen between the specimen chamber and the detecting chamber. The through hole can be opened or self-sealed. The sealing or opening of the through hole controls whether or not the liquid specimen in the specimen chamber enters the detecting chamber via the through hole. Furthermore, a detection method is provided.

Abstract: Devices, methods and systems effective to evaluate a physical or chemical property of a surfactant-treated biological fluid sample are provided.

Abstract: A device for detecting an analyte in a sample is provided, which comprises: a collecting chamber containing an opening for collecting a liquid sample; a detecting element for detecting an analyte in the liquid sample; and a lid for covering the opening of the collecting chamber. The device further comprises an indicating device thereon to indicate whether or not the lid covers at an appointed position. The operation of the device is very simple.

Abstract: This invention relates, inter alia, to detecting and/or measuring succinylacetone and one or more additional biological analytes using mass spectrometry.

Abstract: Methods for monitoring ionic liquids using vibrational spectroscopy may involve contacting an infrared (IR) transmissive medium with the ionic liquid, recording an IR spectrum of the ionic liquid, and quantifying at least one chemical characteristic of the ionic liquid based on the IR spectrum. The IR spectrum may be recorded ex situ or in situ. Methods for controlling ionic liquid catalyzed processes are also disclosed, wherein a condition of the ionic liquid may be determined during such processes based on IR spectral analysis of the ionic liquid.

Abstract: A method for detecting a taggant molecular structure in a fluid includes providing a molecularly imprinted polymer sensor device, contacting a molecularly imprinted crosslinked star polymer with the fluid, and correlating a color change in the fluid with the amount of the taggant molecular structure in the fluid. The device has polymer arms attached to a core, and the core has molecular sized cavities adapted to selectively receive and bind displacement molecules having the taggant molecular structure and a colorimetric indicator. The displacement molecule is selectively removed from the molecularly imprinted crosslinked polymer upon exposure to the taggant molecular structure in the fluid thereby indicating the presence of the taggant molecular structure in the fluid based on a loss of color along a length of a housing.

Abstract: Isobaric reagents for labeling analytes are provided. The isobaric reagents have facile design and synthesis that allows for differential labeling of an unlimited number of analyte samples.

Abstract: An ultrasensitive method for detecting non-aromatic non-planar nitroamine analytes in a sample is provided.

Abstract: The invention relates to methods for detecting the presence of a compound of formula I in a biological test sample: where R2, R3, and R4 are as defined in the specification; or a salt thereof.

Abstract: The present disclosure relates to methods for weight management in an individual in need thereof by determining the level of renal sufficiency of the individual and prescribing or administering a therapeutically effective amount of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine or a pharmaceutically acceptable salt, solvate or hydrate thereof to the individual, provided that the individual has a level of renal sufficiency selected from the group consisting of: no renal impairment, mild renal impairment, and moderate renal impairment.

Abstract: Methods of treating a wound, an ulcer and/or a burn responsive to inhibition of xanthine oxidoreductase to thereby reduce uric acid in an animal are provided wherein the methods include topical administration of a therapeutic agent effective for treatment of the wound, the ulcer and/or the burn wherein the therapeutic agent inhibits xanthine oxidoreductase to thereby reduce uric acid in the wound, ulcer and/or burn. Also provided are methods and kits for determining the severity of a wound, a burn and/or an ulcer including the step of detecting one or more of (i) a level of uric acid; (ii) a level of one or more uric acid precursors; and (iii) a presence, or absence of or level of xanthine oxidoreductase.

Abstract: This invention pertains to methods, mixtures, kits and compositions pertaining to analyte determination by mass spectrometry using labeling reagents that comprise a nucleophilic reactive group that reacts with a functional group of an analyte to produce a labeled analyte. The labeling reagents can be used as isobaric sets, mass differential labeling sets or in a combination of isobaric and mass differential labeling sets.

Abstract: The present invention is related to methods for preventing or retarding (i.e., inhibiting) yellow color or peroxide formation in a composition. The present invention is also related to methods of reducing or decreasing the amount of yellow color or peroxide in a composition. More specifically, the present invention relates to the use of an antioxidant, an oxygen scavenger, pH, a chelating agent, and/or at least two factors in the methods of the invention. The present invention is also related to methods for predicting the rate of yellow color or peroxide formation in a composition.

Abstract: Systems and methods are provided for monitoring a immunosuppressant drug level and renal function, hepatic function, or a combination thereof in a patient, comprising obtaining a small volume blood sample from the patient; determining the level of at least one immunosuppressant drug in the small volume blood sample and determining the level of a second immunosuppressant drug or analyzing the renal function, the hepatic function, or a combination thereof in the patient. In some embodiments, the immunosuppressant drug levels are determined using a liquid chromatography tandem mass spectrometry (LC-MS/MS) procedure. Also provided are kits for use in any of the systems and methods described herein.

Abstract: The invention relates to methods and compositions for the rapid detection of small ligands, such as cyanide, carbon monoxide or azide, in small quantities. Specifically, metmyoglobin is used to bind small ligands which yield a product with a characteristic absorbance spectrum that is detectable and quantifiable. Also disclosed is a kit for detecting small ligands with metmyoglobin, which is portable and provides for practice of the invention without the use of harsh solvents or chemical reagents.

Abstract: The present invention is related to the use of 5-hydroxymethylcytosine or a biomolecule having general structure of 5-hydroxymethycytosine as a biomarker for the detection, treatment monitoring, and prognostic prediction of cancer.

Abstract: Methods and kits for diagnosis and staging of shock, and especially non-septic shock are presented in which protease activities and/or volatile compounds are measured from a biological sample to so identify and/or stage shock.

Abstract: The present invention is directed to treatment methods of administering tetrahydrobiopterin, including in oral dosage forms, in intravenous formulations, and with food. Also disclosed herein are biopterin assays for measuring the amount of biopterin and metabolites of biopterin in a sample.

Abstract: The present invention relates to the field of medical treatments for diseases and disorders. More specifically, the present invention relates to the use of the lanthionine synthetase component C-like (LANCL) proteins as therapeutic targets for novel classes of anti-inflammatory, immune regulatory and antidiabetic drugs.

Abstract: Disclosed are magnetic nanosensors or transducers that permit measurement of a physical parameter in an analyte via magnetic reasonance measurements, in particular of non-agglomerative assays. More particularly, in certain embodiments, the invention relates to designs of nanoparticle reagents and responsive polymer coated magnetic nanoparticles. Additionally provided are methods of use of nanoparticle reagents and responsive polymer coated magnetic nanoparticles for the detection of a stimulus or an analyte with NMR detectors.

Abstract: This invention pertains to methods, kits and/or compositions for the determination of analytes by mass analysis using unique labeling reagents or sets of unique labeling reagents. The labeling reagents can be isomeric or isobaric and can be used to produce mixtures suitable for multiplex analysis of the labeled analytes.

Abstract: A method of detecting melamine which includes providing a quantity of SERS-active particles and mixing the SERS-active particles with a solution containing melamine. The method further includes detecting a surface enhanced Raman spectrum of the melamine. The foregoing method may optionally include aggregating the SERS-active particles. Aggregation may occur before or after the SERS-active particles are mixed with a solution containing melamine. The method of detecting melamine may optionally include concentration of the SERS-active particles. The method may further include mixing a chaotropic agent having a higher affinity for a selected binding site than melamine into the solution containing melamine. The method may further include mixing a quantity of a SERS-active standard having a known SERS spectrum with the solution containing melamine and SERS-active particles. Assay apparatus and systems are also disclosed.

Abstract: This invention relates, inter alia, to detecting and/or measuring succinylacetone and one or more additional biological analytes using mass spectrometry.

Abstract: Chemiluminescent detection of metabolic by-products of inosine and hypoxanthine is used to diagnose ischemic events such as early acute cardiac ischemia.

Abstract: The invention provides an ELISA assay for the determination of serum mast cell ?-tryptase levels using rabbit anti-tryptase as the capture antibody and alkaline phosphatase conjugated G3 as the detecting antibody. Luminescent substrate CPSD was used to enhance the assay sensitivity. Also provided are methods for aiding in the diagnosis of irritable bowel syndrome by detecting the serum level of ?-tryptase, histamine and/or prostaglandin E2.

Abstract: A method for measuring the concentration of creatinine includes the steps of: (A) mixing a sample containing creatinine with a creatinine quantitative reagent including 1-methoxy-5-methylphenazinium in the absence of picric acid and any enzyme responsive to creatinine, to cause the creatinine to reduce the 1-methoxy-5-methylphenazinium; (B) electrochemically or optically measuring the amount of the 1-methoxy-5-methylphenazinium reduced in the step (A); and (C) determining the concentration of the creatinine contained in the sample from the amount of the reduced 1-methoxy-5-methylphenazinium measured in the step (B).

Abstract: The present invention generally relates to Magnetic Resonance Imaging (MRI) analysis of the location, presence, and/or quantity of a particular molecule or material. In some embodiments, the invention relates to compositions and methods for determination of an analyte, wherein a compositions may produce an MRI signal that can be affected by the presence of a particular composition (e.g., analyte). In a particular embodiment, the composition comprises a protein. The invention also provides related nucleic acid molecules, polypeptides, and fragments thereof. Compositions of the invention may exhibit reduced toxicity and may be readily delivered in vivo. Various embodiments of the invention may be useful as sensors, diagnostic tools, and the like.

Abstract: Molecular bioprofiles comprising biologically correlated and relevant analytes that impact the biological state of a human health condition compared to a control population are provided. These molecular bioprofiles are useful in several ways including but not limited to, monitoring a disease or condition's progression, evaluating the impact of an agent or compound on a disease or condition, evaluating the impact of a lifestyle change on a disease or condition and assessing the risk of the disease or condition to a subject. Type II diabetes molecular bioprofiles are of particular interest.

Abstract: A method of optimizing a hydrogen sulfide scavenger blend that includes selecting a hydrogen sulfide scavenger blend comprising at least two hydrogen sulfide scavengers; determining a scavenging capacity for the blend; modifying at least one blend parameter based on the determined scavenging capacity; redetermining the scavenging capacity for the modified blend; and selecting an optimized blend from the blend and the modified blend is disclosed.

Abstract: The present invention provides a method for capacitive detection of the presence of target sample on a substrate, which comprises the steps of: binding a target sample to selective binding sites on the substrate, the target sample being directly or indirectly labeled with conductive labels, and sensing the presence of the bound conductive labels to a binding site to thereby determine the presence of the target sample. The sensing step is carried out by a capacitive detection of the presence of the conductive labels. The present invention also provides a capacitive sensor device for determining the presence of a target sample. Conductive labels are directly or indirectly couplable to the target sample.

Abstract: A process for obtaining 2?-halo-4-methylbiphenyls is described, which comprises reacting 4 halotoluene with a 1,2-dihalobenzene in the presence of elemental metal such as magnesium, lithium or zinc, wherein 0 to 0.9 molar, particularly 0 to 0.2 molar excess of 4-halotoluene in regard to 1,2-dihalobenzene is used, and arised organometal intermediates are quenched by elemental mental halogen. In addition, the coupling of arised 2?-halo-4-methylbiphenyls with 2-(1-propyl)-4-methyl-6-(1?-methylbenzimidazole-2-il)benzimidazole to afford 3?-(2?-halo-biphenyl-4-ylmethyl)-1,7?-dimethyl-2?-propyl-1H,3?H-[2,5?]bibenzoimidazolyl, which can be further converted to organometallic compound and said organometallic compound is further reacted with formic acid derivative, such as N,N-dimethylformamide, alkylformiate or carbon dioxide to obtain telmisartan, is also described.